Clinical trial · Observational
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Empliciti® (Elotuzumab) Post-Marketing Surveillance Study for Patients With Multiple Myeloma in Taiwan
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study aimed to assess the safety of elotuzumab when used in combination with pomalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma (RRMM) in participants who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The study will also assess the safety of elotuzumab when used in combination with lenalidomide and dexamethasone in RRMM participants who had received one to three prior therapies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Elotuzumab in combination with lenalidomide and dexamethasone | Drug | — | UNRESOLVED |
| Elotuzumab in combination with pomalidomide and dexamethasone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Treated with Elotuzumab in combination with pomalidomide and dexamethasone
- interventionNames
- Drug: Elotuzumab in combination with pomalidomide and dexamethasone
- label
- Treated with Elotuzumab in combination with lenalidomide and dexamethasone
- interventionNames
- Drug: Elotuzumab in combination with lenalidomide and dexamethasone
Primary outcomes (2)
- measure
- Number of participants with adverse events
- timeFrame
- 25 weeks from start of treatment, or during a 30-day follow-up period following treatment discontinuation (whichever time period falls at a later date)
- description
- Assessed according to NCI CTCAE v5.0
- measure
- Number of participants with adverse events of special interest
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Confirmed diagnosis of RRMM * Received ≥ 2 prior therapies including lenalidomide and a proteasome inhibitor * Planning to receive elotuzumab in combination with pomalidomide and dexamethasone at physician's medical judgement OR * Age ≥ 18 years * Confirmed diagnosis of RRMM * Received one to three prior therapies * Planning to receive elotuzumab in combination with lenalidomide and dexamethasone at physician's medical judgement Exclusion Criteria: * Participants with therapeutic indications for which elotuzumab in combination with pomalidomide/lenalidomide and dexamethasone has not been approved in Taiwan * Participants who are contraindicated for treated with elotuzumab in combination with pomalidomide/lenalidomide and dexamethasone (as described in the Taiwan label) * Participants who participate in other interventional clinical trials
References
Publications (0)
Data not yet available